J Korean Med Sci.  2013 Jan;28(1):106-113. 10.3346/jkms.2013.28.1.106.

Growth after Hematopoietic Stem Cell Transplantation in Children with Acute Myeloid Leukemia

• Chung SJ
• Park SW
• Kim MK
• Kang MJ
• Lee YA
• Lee SY
• Shin CH
• Yang SW
• Kang HJ
• Park KD
• Shin HY
• Ahn HS

• KMID: 2158009
• DOI: http://doi.org/10.3346/jkms.2013.28.1.106

Abstract

Previous studies have shown that hematopoietic stem cell transplantation (HSCT) may result in growth impairment. The purpose of this study was to evaluate the growth during 5 yr after HSCT and to determine factors that influence final adult height (FAH). We retrospectively reviewed the medical records of acute myeloid leukemia (AML) patients who received HSCT. Among a total of 37 eligible patients, we selected 24 patients who began puberty at 5 yr after HSCT (Group 1) and 19 patients who reached FAH without relapse (Group 2). In Group 1, with younger age at HSCT, sex, steroid treatment, hypogonadism and hypothyroidism were not significantly associated with growth impairment 5 yr after HSCT. History of radiotherapy (RT) significantly impaired the 5 yr growth after HSCT. Chronic graft-versus-host disease (cGVHD) only temporarily impaired growth after HSCT. In Group 2, with younger age at HSCT, steroid treatment and hypogonadism did not significantly reduce FAH. History of RT significantly reduced FAH. Growth impairment after HSCT may occur in AML patients, but in patients without a history of RT, growth impairment seemed to be temporary and was mitigated by catch-up growth.

Keyword

Hematopoietic Stem Cell Transplantation; Growth; Radiotherapy; Total Body Irradiation; Acute Myeloid Leukemia

MeSH Terms

Adolescent
Body Height/*radiation effects
Child
Child, Preschool
Female
Graft vs Host Disease/pathology/prevention & control
*Hematopoietic Stem Cell Transplantation
Humans
Hypogonadism/drug therapy/pathology
Infant
Leukemia, Myeloid, Acute/radiotherapy/*therapy
Male
Recurrence
Retrospective Studies
Risk Factors
Steroids/therapeutic use
Steroids

Figure

• 

  Fig. 1 Schematic description of classification of 97 acute myeloid leukemia patients. HSCT, hematopoietic stem cell transplantation, FAH, final adult height.

• 

  Fig. 2 Growth of the RT patients. Height Z-scores of RT patients at yearly intervals after HSCT were described (S1, S2 and S3, CI subjects; S4, S5 and S6, CSRT subjects; S7, TBI subject). Dotted lines indicate GH treatment period. After starting the treatment, height Z-scores increased or stopped decreasing. One RT patient (S4) seemed to show catch-up growth after 5 yr, but this growth was pubertal growth. RT, radiotherapy; HSCT, hematopoietic stem cell transplantation; GH Tx, growth hormone treated subject (+, treated; -, non-treated); CI, cranial irradiation; CSRT, craniospinal radiotherapy; TBI, total body irradiation; Group 1, patients whose puberty began at least 5 yr after HSCT; Group 2, patients who reached final adult height without relapse.

• 

  Fig. 3 Scatterplots of height Z-scores at yearly intervals after HSCT with linear regression lines and smooth curved fit lines with standard error intervals (Group 1). A point indicates the height Z-score 0 to 5 yr after HSCT for one patient. Jagged lines indicate smooth curved fit lines. Pink-colored points and smooth curved fit lines indicate the data of non-RT patients in (B, C). Note that the smooth curved fit line shows that only the height of RT subjects (blue) among the cGVHD and steroid-treated patients continues to decrease in the 5 yr after HSCT. RT, radiotherapy; cGVHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.

• 

  Fig. 4 Mean height Z-score at HSCT, at final adult height and mean target height Z-score comparing between non-RT and RT patients (Group 2). HSCT, hematopoietic stem cell transplantation; RT, radiotherapy.

Reference

1. Bernard F, Bordigoni P, Simeoni MC, Barlogis V, Contet A, Loundou A, Thuret I, Leheup B, Chambost H, Play B, et al. Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI. Bone Marrow Transplant. 2009. 43:637–642.

2. Sanders JE, Guthrie KA, Hoffmeister PA, Woolfrey AE, Carpenter PA, Appelbaum FR. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood. 2005. 105:1348–1354.

3. Bakker B, Oostdijk W, Bresters D, Walenkamp MJ, Vossen JM, Wit JM. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant. 2004. 33:1049–1056.

4. Cohen A, Rovelli A, Bakker B, Uderzo C, van Lint MT, Esperou H, Gaiero A, Leiper AD, Dopfer R, Cahn JY, et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood. 1999. 93:4109–4115.

5. Chemaitilly W, Boulad F, Heller G, Kernan NA, Small TN, O'Reilly RJ, Sklar CA. Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation. Bone Marrow Transplant. 2007. 40:29–35.

6. Couto-Silva AC, Trivin C, Esperou H, Michon J, Baruchel A, Lemaire P, Brauner R. Final height and gonad function after total body irradiation during childhood. Bone Marrow Transplant. 2006. 38:427–432.

7. De Simone M, Verrotti A, Iughetti L, Palumbo M, Di Bartolomeo P, Olioso P, Rosato T. Final height of thalassemic patients who underwent bone marrow transplantation during childhood. Bone Marrow Transplant. 2001. 28:201–205.

8. Frisk P, Arvidson J, Gustafsson J, Lonnerholm G. Pubertal development and final height after autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant. 2004. 33:205–210.

9. Tauchmanova L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, Rotoli B, Colao A. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer. 2002. 95:1076–1084.

10. Sanders JE, Pritchard S, Mahoney P, Amos D, Buckner CD, Witherspoon RP, Deeg HJ, Doney KC, Sullivan KM, Appelbaum FR, et al. Growth and development following marrow transplantation for leukemia. Blood. 1986. 68:1129–1135.

11. Adan L, de Lanversin ML, Thalassinos C, Souberbielle JC, Fischer A, Brauner R. Growth after bone marrow transplantation in young children conditioned with chemotherapy alone. Bone Marrow Transplant. 1997. 19:253–256.

12. Shalitin S, Phillip M, Stein J, Goshen Y, Carmi D, Yaniv I. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant. 2006. 37:1109–1117.

13. Huma Z, Boulad F, Black P, Heller G, Sklar C. Growth in children after bone marrow transplantation for acute leukemia. Blood. 1995. 86:819–824.

14. Afify Z, Shaw PJ, Clavano-Harding A, Cowell CT. Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. Bone Marrow Transplant. 2000. 25:1087–1092.

15. Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, Sandlund JT, Kun LE, Bowman LC, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol. 2000. 18:3273–3279.

16. Lee DH, Chung NG, Cho B, Kim HK, Kang HJ, Shin HY, Ahn HS, Yoo KH, Sung KW, Koo HH, et al. Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea. J Korean Med Sci. 2010. 25:9–15.

17. Korea Center for Disease Control and Prevention TKPS, The Committee for the Development of Growth Standard for Korean Children and Adolescents. 2007 Korean Children and Adolescents Growth Standard. Government report online. 2007. accessed on 4 October 2012. Seoul: Division of Chronic Disease Surveillance;Available at http://www.cdc.go.kr/webcdc/.

18. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 1959. 2nd ed. California: Standford University Press.

19. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969. 44:291–303.

20. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970. 45:13–23.

21. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003. 9:215–233.

22. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990. 300:230–235.

23. Senn S, Stevens L, Chaturvedi N. Repeated measures in clinical trials: simple strategies for analysis using summary measures. Stat Med. 2000. 19:861–877.

24. Siebler T, Shalet SM, Robson H. Effects of chemotherapy on bone metabolism and skeletal growth. Horm Res. 2002. 58:80–85.

25. Roman J, Villaizan CJ, Garcia-Foncillas J, Salvador J, Sierrasesumaga L. Growth and growth hormone secretion in children with cancer treated with chemotherapy. J Pediatr. 1997. 131:105–112.

26. Bakker B, Massa GG, Oostdijk W, Van Weel-Sipman MH, Vossen JM, Wit JM. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies. Eur J Pediatr. 2000. 159:31–37.

27. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA. Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr. 2007. 150:370–375.

28. Narumi S, Shimada H, Shimasaki N, Takahashi T, Hasegawa T, Mori T. Growth-chart-based qualitative evaluation of height growth after hematopoietic stem cell transplantation. Pediatr Transplant. 2006. 10:26–31.

29. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010. 95:167–177.

30. Isfan F, Kanold J, Merlin E, Contet A, Sirvent N, Rochette E, Poiree M, Terral D, Carla-Malpuech H, Reynaud R, et al. Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA). Bone Marrow Transplant. 2012. 47:684–693.